Shares of Ipca Laboratories were trading higher at Rs 1,354 on Thursday. The stock showed a marginal increase of 0.15 percent. Trading activity suggested increased investor interest in the stock, which is a constituent of the Nifty Midcap 150 index at 1:58 pm.
Financial Overview:
Ipca Laboratories' financial performance shows consistent growth in revenue and net profit over the years. Here's a summary of the company's consolidated financial data:
Consolidated Yearly Data:
| Year | Revenue (Rs Crore) | Net Profit (Rs Crore) | EPS | BVPS | ROE | Debt to Equity |
|---|---|---|---|---|---|---|
| 2021 | Rs 5,419.99 Crore | Rs 1,148.84 Crore | 45.01 | 371.79 | 24.24 | 0.05 |
| 2022 | Rs 5,829.79 Crore | Rs 910.95 Crore | 34.85 | 219.51 | 16.09 | 0.14 |
| 2023 | Rs 6,244.32 Crore | Rs 491.93 Crore | 18.58 | 233.16 | 8.06 | 0.25 |
| 2024 | Rs 7,705.04 Crore | Rs 529.21 Crore | 25.82 | 304.57 | 8.64 | 0.22 |
| 2025 | Rs 8,939.59 Crore | Rs 787.53 Crore | 35.14 | 273.88 | 10.61 | 0.19 |
The revenue has increased from Rs 5,419.99 Crore in 2021 to Rs 8,939.59 Crore in 2025. Net profit also saw an increase from Rs 529.21 Crore in 2024 to Rs 787.53 Crore in 2025.
Consolidated Quarterly Data:
| Quarter | Sales (Rs Crore) | Other Income (Rs Crore) | Total Income (Rs Crore) | Total Expenditure (Rs Crore) | EBIT (Rs Crore) | Interest (Rs Crore) | Tax (Rs Crore) | Net Profit (Rs Crore) |
|---|---|---|---|---|---|---|---|---|
| Jun 2024 | Rs 2,092 Crore | Rs 20 Crore | Rs 2,113 Crore | Rs 1,798 Crore | Rs 314 Crore | Rs 24 Crore | Rs 91 Crore | Rs 198 Crore |
| Sep 2024 | Rs 2,354 Crore | Rs 26 Crore | Rs 2,381 Crore | Rs 2,013 Crore | Rs 367 Crore | Rs 22 Crore | Rs 99 Crore | Rs 245 Crore |
| Dec 2024 | Rs 2,245 Crore | Rs 20 Crore | Rs 2,265 Crore | Rs 1,880 Crore | Rs 384 Crore | Rs 16 Crore | Rs 90 Crore | Rs 277 Crore |
| Mar 2025 | Rs 2,246 Crore | Rs 25 Crore | Rs 2,272 Crore | Rs 2,123 Crore | Rs 149 Crore | Rs 21 Crore | Rs 62 Crore | Rs 65 Crore |
| Jun 2025 | Rs 2,308 Crore | Rs 32 Crore | Rs 2,341 Crore | Rs 1,992 Crore | Rs 349 Crore | Rs 18 Crore | Rs 96 Crore | Rs 234 Crore |
The sales increased from Rs 2,092 Crore in June 2024 to Rs 2,308 Crore in June 2025.
Key Ratios (Year-Ending March 2025):
- Basic EPS: Rs 35.14
- Book Value per Share: Rs 273.88
- Face Value: Rs 1
- Debt to Equity: 0.19
- Interest Coverage Ratio: 21.42
Ipca Laboratories has a history of corporate actions, including dividends and stock splits. Recent announcements include disclosures under SEBI regulations and analyst/investor meetings.
Dividends: The company has consistently announced dividends. The final dividend of Rs 2 per share (200%) was announced on May 29, 2025, with an effective date of August 5, 2025.
Bonus Shares: A bonus issue was announced on October 27, 2004, with a bonus ratio of 1:1 and an ex-bonus date of January 28, 2005.
Stock Splits: The company executed a stock split on January 10, 2022, changing the face value from Rs 2 to Rs 1 and another split on March 22, 2010, changing the face value from Rs 10 to Rs 2.
Ipca Laboratories is moved by 0.15 percent.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
